Cara Therapeutics (CARA) Commences CR845 Phase 2b Enrollment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Wall St rallies on bright earnings, megacaps' support
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil falls back after robust EU data as Mideast tensions linger
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
Cara Therapeutics Initiates Enrollment in Phase 2b Trial of Peripherally Acting Kappa Opioid Agonist, Oral CR845, in Chronic Pain Patients
September 15, 2016 7:00 AM EDTTrial to evaluate three tablet strengths of CR845 versus placebo in approximately 330 osteoarthritis patients
Top-line data expected in first half of 2017
STAMFORD, Conn., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced the initiation of patient enrollment in a Phase 2b trial of an oral tablet formulation of its peripherally selective kappa opioid agonist, CR845, for... More
